These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24132869)

  • 1. A new option for glycemic control: insulin degludec, a new-generation basal insulin with an ultralong duration of action.
    Drab SR; Philis-Tsimikas A
    Pharmacotherapy; 2014 Mar; 34(3):291-302. PubMed ID: 24132869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
    Goldman J; Kapitza C; Pettus J; Heise T
    Curr Med Res Opin; 2017 Oct; 33(10):1821-1831. PubMed ID: 28537449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review.
    Vora J; Heise T
    Diabetes Obes Metab; 2013 Aug; 15(8):701-12. PubMed ID: 23451796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
    Ericsson Å; Pollock RF; Hunt B; Valentine WJ
    J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Insulins and New Aspects in Insulin Delivery.
    Woo VC
    Can J Diabetes; 2015 Aug; 39(4):335-43. PubMed ID: 26233724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic compliance and flexibility in the use of basal insulins].
    Costa Gil JE; Litwak LE; Fuente GV; Faingold MC
    Medicina (B Aires); 2014; 74(4):273-81. PubMed ID: 25188652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes.
    Hompesch M; Patel DK; LaSalle JR; Bolli GB
    Postgrad Med; 2019 Mar; 131(2):117-128. PubMed ID: 30691343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translating structure to clinical properties of an ideal basal insulin.
    Unnikrishnan AG; Bantwal G; Sahay RK
    J Assoc Physicians India; 2014 Jan; 62(1 Suppl):15-20. PubMed ID: 25330627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoglycemia rates with basal insulin analogs.
    Little S; Shaw J; Home P
    Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S53-64. PubMed ID: 21668338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating to target in type 2 diabetes: the BEGIN trial programme.
    Wangnoo SK; Chowdhury S; Rao PV
    J Assoc Physicians India; 2014 Jan; 62(1 Suppl):21-6. PubMed ID: 25330628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin preparations with prolonged effect.
    Owens DR
    Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S5-14. PubMed ID: 21668337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDegAsp: a novel soluble insulin analogs combination.
    Ma Z; Parkner T; Christiansen JS; Laursen T
    Expert Opin Biol Ther; 2012 Nov; 12(11):1533-40. PubMed ID: 22946603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future of basal insulin supplementation.
    Simon AC; DeVries JH
    Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S103-8. PubMed ID: 21568722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basal insulin analogues in the management of diabetes mellitus: What progress have we made?
    Owens DR; Matfin G; Monnier L
    Diabetes Metab Res Rev; 2014 Feb; 30(2):104-19. PubMed ID: 24026961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of insulin development: focus on key parameters.
    Tibaldi JM
    Adv Ther; 2012 Jul; 29(7):590-619. PubMed ID: 22843207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing the replacement of basal insulin in type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era.
    Bolli GB; Andreoli AM; Lucidi P
    Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S43-52. PubMed ID: 21668336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin analogues in the management of diabetes.
    Vázquez-Carrera M; Silvestre JS
    Methods Find Exp Clin Pharmacol; 2004; 26(6):445-61. PubMed ID: 15349139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin degludec. Uncertainty over cardiovascular harms.
    Prescrire Int; 2014 Jun; 23(150):149. PubMed ID: 25121146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Usefulness and limitations of basal insulin replacement in type 2 diabetes].
    Hirata E; Ohmori K; Nagai S
    Nihon Rinsho; 2015 Mar; 73(3):458-64. PubMed ID: 25812373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.